PE20230412A1 - Compuestos para su uso en afecciones inflamatorias - Google Patents
Compuestos para su uso en afecciones inflamatoriasInfo
- Publication number
- PE20230412A1 PE20230412A1 PE2022001880A PE2022001880A PE20230412A1 PE 20230412 A1 PE20230412 A1 PE 20230412A1 PE 2022001880 A PE2022001880 A PE 2022001880A PE 2022001880 A PE2022001880 A PE 2022001880A PE 20230412 A1 PE20230412 A1 PE 20230412A1
- Authority
- PE
- Peru
- Prior art keywords
- unsubstituted
- substituted
- alkyl
- independently selected
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000004968 inflammatory condition Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 241000689227 Cora <basidiomycete fungus> Species 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Referido a un compuesto de formula I, en donde X es O o NH; Y es CO o -COCH(CH3)CO-; cada n y p se selecciona independientemente entre 0 y 1; y q es 0, 1 o 2; cada R1, R3, R5, R9, R11 y R15 se selecciona independientemente entre H, alquilo C1-C6 sustituido o sin sustituir; entre otros; R2 es H, CORa, COORa, entre otros; cada R4, R8, R10, R12 y R16 se selecciona independientemente entre H y alquilo C1-C6 sustituido o sin sustituir; cada R7 y R13 es independientemente H, alquilo C1-C6 sustituido o sin sustituir, entre otros; R6 y R14 se selecciona independientemente entre H y alquilo C1-C6 sustituido o sin sustituir, entre otros; R17 es H, CORa, COORa, CONHRb, entre otros. En donde estos compuestos activan de receptores de tipo Toll. Tambien se refiere a una composicion farmaceutica que comprende dicho compuesto, una sal o estereoisomero del mismo y un portador farmaceuticamente aceptable, la fabricacion de un medicamento que contiene dicho compuesto para el tratamiento de la inflamacion, tales como la inflamacion inducida por patogenos o infeccion virica.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382152 | 2020-03-02 | ||
| EP20382192 | 2020-03-13 | ||
| EP20382266 | 2020-04-02 | ||
| EP20382339 | 2020-04-27 | ||
| EP20382815 | 2020-09-16 | ||
| EP20382816 | 2020-09-16 | ||
| EP21382059 | 2021-01-25 | ||
| PCT/EP2021/055187 WO2021175857A1 (en) | 2020-03-02 | 2021-03-02 | Compounds for use in inflammatory conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230412A1 true PE20230412A1 (es) | 2023-03-07 |
Family
ID=74732953
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001795A PE20230606A1 (es) | 2020-03-02 | 2021-03-02 | Compuestos para su uso en infecciones viricas |
| PE2022001880A PE20230412A1 (es) | 2020-03-02 | 2021-03-02 | Compuestos para su uso en afecciones inflamatorias |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001795A PE20230606A1 (es) | 2020-03-02 | 2021-03-02 | Compuestos para su uso en infecciones viricas |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20230295236A1 (es) |
| EP (2) | EP4114435A1 (es) |
| JP (2) | JP2023517535A (es) |
| KR (2) | KR20220151643A (es) |
| CN (2) | CN115461067A (es) |
| AU (2) | AU2021232535A1 (es) |
| BR (2) | BR112022016604A2 (es) |
| CA (2) | CA3169540A1 (es) |
| CL (2) | CL2022002396A1 (es) |
| CO (2) | CO2022014031A2 (es) |
| IL (2) | IL296068A (es) |
| MX (2) | MX2022010926A (es) |
| PE (2) | PE20230606A1 (es) |
| TW (2) | TW202146038A (es) |
| UY (2) | UY39109A (es) |
| WO (2) | WO2021175857A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024165764A1 (en) * | 2023-02-10 | 2024-08-15 | Pharma Mar, S.A. | Plitidepsin for use in the treatment of non-integrated dna viral infections |
| CN117285611B (zh) * | 2023-11-24 | 2024-02-09 | 中国海洋大学 | 一种来源于海鞘的抗炎寡肽及其在制备药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8922026D0 (en) * | 1989-09-29 | 1989-11-15 | Pharma Mar Sa | Novel anti-viral and cytotoxic agent |
| US6156724A (en) * | 1996-06-07 | 2000-12-05 | Rinehart; Kenneth L. | Uses of didemnins as immunomodulating agents |
| GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| MXPA02009943A (es) | 2000-04-07 | 2003-04-25 | Univ Pennsylvania | Analogos de tamandarin y didemnin y metodos para hacerlos y usarlos. |
| UA76718C2 (uk) | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
| JP2006523214A (ja) | 2003-03-21 | 2006-10-12 | ジユーリー，マデレーン・エム | タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法 |
| WO2011020913A2 (en) | 2009-08-21 | 2011-02-24 | Pharma Mar, S.A. | Cyclodepsipeptide antiviral compounds |
-
2021
- 2021-03-02 WO PCT/EP2021/055187 patent/WO2021175857A1/en active Application Filing
- 2021-03-02 US US17/908,526 patent/US20230295236A1/en active Pending
- 2021-03-02 BR BR112022016604A patent/BR112022016604A2/pt unknown
- 2021-03-02 BR BR112022016675A patent/BR112022016675A2/pt unknown
- 2021-03-02 CA CA3169540A patent/CA3169540A1/en active Pending
- 2021-03-02 MX MX2022010926A patent/MX2022010926A/es unknown
- 2021-03-02 IL IL296068A patent/IL296068A/en unknown
- 2021-03-02 UY UY0001039109A patent/UY39109A/es unknown
- 2021-03-02 EP EP21708237.9A patent/EP4114435A1/en active Pending
- 2021-03-02 PE PE2022001795A patent/PE20230606A1/es unknown
- 2021-03-02 AU AU2021232535A patent/AU2021232535A1/en active Pending
- 2021-03-02 KR KR1020227034317A patent/KR20220151643A/ko unknown
- 2021-03-02 JP JP2022552937A patent/JP2023517535A/ja active Pending
- 2021-03-02 AU AU2021231197A patent/AU2021231197A1/en active Pending
- 2021-03-02 US US17/908,533 patent/US20230159594A1/en active Pending
- 2021-03-02 TW TW110107293A patent/TW202146038A/zh unknown
- 2021-03-02 WO PCT/EP2021/055147 patent/WO2021175831A2/en active Application Filing
- 2021-03-02 CN CN202180018363.6A patent/CN115461067A/zh active Pending
- 2021-03-02 CN CN202180018734.0A patent/CN115666616A/zh active Pending
- 2021-03-02 UY UY0001039110A patent/UY39110A/es unknown
- 2021-03-02 TW TW110107292A patent/TW202144381A/zh unknown
- 2021-03-02 PE PE2022001880A patent/PE20230412A1/es unknown
- 2021-03-02 JP JP2022552946A patent/JP2023517536A/ja active Pending
- 2021-03-02 KR KR1020227034280A patent/KR20220150350A/ko unknown
- 2021-03-02 MX MX2022010921A patent/MX2022010921A/es unknown
- 2021-03-02 EP EP21708019.1A patent/EP4114433A2/en active Pending
- 2021-03-02 IL IL296069A patent/IL296069A/en unknown
- 2021-03-02 CA CA3169544A patent/CA3169544A1/en active Pending
-
2022
- 2022-09-02 CL CL2022002396A patent/CL2022002396A1/es unknown
- 2022-09-02 CL CL2022002395A patent/CL2022002395A1/es unknown
- 2022-09-30 CO CONC2022/0014031A patent/CO2022014031A2/es unknown
- 2022-09-30 CO CONC2022/0014093A patent/CO2022014093A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023517535A (ja) | 2023-04-26 |
| CN115666616A (zh) | 2023-01-31 |
| BR112022016675A2 (pt) | 2022-10-11 |
| US20230159594A1 (en) | 2023-05-25 |
| KR20220151643A (ko) | 2022-11-15 |
| CO2022014031A2 (es) | 2022-10-21 |
| KR20220150350A (ko) | 2022-11-10 |
| MX2022010921A (es) | 2022-09-29 |
| CL2022002396A1 (es) | 2023-06-30 |
| WO2021175831A3 (en) | 2021-10-14 |
| PE20230606A1 (es) | 2023-04-10 |
| AU2021231197A1 (en) | 2022-10-06 |
| EP4114433A2 (en) | 2023-01-11 |
| EP4114435A1 (en) | 2023-01-11 |
| TW202146038A (zh) | 2021-12-16 |
| IL296069A (en) | 2022-11-01 |
| CA3169544A1 (en) | 2021-09-10 |
| UY39110A (es) | 2021-09-30 |
| UY39109A (es) | 2021-09-30 |
| WO2021175831A2 (en) | 2021-09-10 |
| MX2022010926A (es) | 2022-09-29 |
| WO2021175857A1 (en) | 2021-09-10 |
| US20230295236A1 (en) | 2023-09-21 |
| CN115461067A (zh) | 2022-12-09 |
| AU2021232535A1 (en) | 2022-10-06 |
| CA3169540A1 (en) | 2021-09-10 |
| CL2022002395A1 (es) | 2023-06-30 |
| BR112022016604A2 (pt) | 2022-10-11 |
| TW202144381A (zh) | 2021-12-01 |
| CO2022014093A2 (es) | 2022-11-18 |
| JP2023517536A (ja) | 2023-04-26 |
| IL296068A (en) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR114290A1 (es) | Péptidos macrocíclicos contra actinetobacter baumannii | |
| PE20230412A1 (es) | Compuestos para su uso en afecciones inflamatorias | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| AR064874A1 (es) | Derivados de hexahidro y tetrahidropterinas,composiciones farmaceuticas que los contienen y usos de las mismas en trastornos cardiovasculares y psiquiatricos entre otros | |
| AR030243A1 (es) | Carboxamidas heterociclicas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento antiviral y metodo in vitro para inhibir el adn polimerasa viral | |
| AR126076A1 (es) | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar | |
| AR043508A1 (es) | 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores | |
| PE20201256A1 (es) | Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas | |
| RU2010116253A (ru) | Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила | |
| AR042635A1 (es) | Imidazoquinolinas arilsustituidas y composiciones farmaceuticas que las contienen | |
| AR062666A1 (es) | Benzotriazoles como moduladores de quinasas | |
| AR059481A1 (es) | Derivados de 1, 3-dihidro-imidazo[4, 5-c]piridin-2-ona como agonista del receptor tlr7, un metodo para su preparacion, intermediarios de sintesis de los mismos, una composicion farmaceutica que los comprende y su uso en la elaboracion de un medicamento para el tratamiento de infecciones viricas. | |
| AR072610A1 (es) | Composiciones para el tratamiento del dolor y/o la inflamacion | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| AR082994A1 (es) | Derivados de pirazina como bloqueadores del canal epitelial de sodio | |
| AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
| AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| AR054231A1 (es) | Composiciones farmaceuticas | |
| AR082633A1 (es) | Analogos de tetraciclina | |
| PE20090620A1 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
| AR058055A1 (es) | Analogos de feniletilamina y su uso para el tratamiento del glaucoma | |
| AR068466A1 (es) | Cianoisoquinolina | |
| CO6430439A2 (es) | Agonistas del receptor de esfingosina -1- fosfato |